Skip to main content
Alkem Laboratories Limited logo

Alkem Laboratories Limited — Investor Relations & Filings

Ticker · ALKEM ISIN · INE540L01014 LEI · 335800GCAE5WIF4PSG69 BSE.NS Manufacturing
Open in API
Filings indexed 1,788 across all filing types
Latest filing 2026-02-13 Regulatory Filings
Country IN India
Listing BSE.NS ALKEM

About Alkem Laboratories Limited

https://www.alkemlabs.com/

Alkem Laboratories Limited specializes in the development, manufacturing, and marketing of pharmaceutical and nutraceutical products. The company’s portfolio covers a wide range of therapeutic areas, including anti-infectives, gastrointestinal, pain management, and vitamins, minerals, and nutrients. It has also expanded into chronic therapeutic segments such as cardiology, diabetology, neurology, and dermatology. Alkem operates multiple manufacturing facilities and advanced research and development centers dedicated to formulation development and active pharmaceutical ingredients. The company provides branded generics, generic medications, and active pharmaceutical ingredients to various international markets. Its operations are supported by a robust supply chain and a focus on high-quality production standards to meet global regulatory requirements.

Recent filings

Filing Released Lang Actions
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q3 & 9MFY26 Earnings Conference Call'' is ....
Regulatory Filings
2026-02-13 English
Copy of Newspaper Publication
Notice of Dividend Amount Classification · 85% confidence The document is a formal disclosure to the stock exchanges under SEBI LODR Regulation 30, enclosing a newspaper advertisement notifying shareholders of the record date fixed for an interim dividend. This constitutes a shareholder notice regarding dividend details (record date) and therefore best fits the “Notice of Dividend Amount” category.
2026-02-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges regarding the availability of the audio recording of the Q3 and 9 months fiscal year 2026 earnings conference call. It references the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and provides a link to the audio recording on the company's website. The document does not contain any financial data or detailed transcript but is an announcement about the availability of the call recording. The length is only 1039 characters, indicating it is a brief notice rather than a full transcript or report. According to the rules, announcements about availability of call recordings or transcripts are classified as Regulatory Filings (RNS) rather than Call Transcript (CT) or Earnings Release (ER).
2026-02-13 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a strategic intent by Alkem MedTech, a subsidiary of Alkem Laboratories, to acquire a majority stake in Occlutech Holding, Switzerland. It details the transaction terms, business rationale, and expected completion timeline. The document is addressed to stock exchanges and references SEBI regulations, indicating it is a formal announcement. It does not contain financial statements, detailed financial performance data, or management analysis typical of annual or interim reports. It is not a transcript, audit report, or governance document. The content focuses on a significant corporate transaction (acquisition) and is presented as a press release rather than a full merger filing or proxy statement. Therefore, the most appropriate classification is a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisitions.
2026-02-13 English
Please find enclosed herewith Press Release.
Regulatory Filings
2026-02-13 English
Please find enclosed herewith the updated details of the Analyst / Institutional Investor meetings.
Regulatory Filings
2026-02-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.